Clinical trials: Severe Asthma Exacerbation
Asthma
Asthma Exacerbation Study
Asthma is a clinical syndrome that is well recognized by health care practitioners, yet asthma pathogenesis still remains poorly understood.
- Trial name
- NCT00853411
- Testing
- prednisone
- Sponsor
- University of Pittsburgh
Asthma Acute, Exacerbation of Allergic Asthma
Nebulized Ketamine for Severe Asthma Attacks in Children
This is a double-blinded, randomised, placebo-controlled trial enrolling 60 children aged 1 to 13 years with severe asthma exacerbation. All participants will receive standard therapy.
- Trial name
- NCT07728851
- Testing
- Ketamine (1 mg/kg)
- Where
- Oman
- Volunteers
- 60 people
- Sponsor
- Sultan Qaboos University
Severe Asthma
Withdrawal of Dupilumab in Severe Asthma
Asthma management has been revolutionised by the development of biological therapies. Dupilumab is an anti-interleukin4 receptor marketed in 2020 for severe asthmatic patients with 2 exacerbations or more within the last 12…
- Trial name
- WIDUSA (NCT06818019)
- Testing
- Stopping dupilumab
- Where
- 29 sites in France
- Volunteers
- 205 people
- Sponsor
- University Hospital, Toulouse
Asthma, Acute Asthma
Effect of Addition of Single Dose of Oral Montelukast to Standard Treatment in Acute Asthma in Preschool Children.
The purpose of this study is to determine if adding single dose of oral montelukast to the standard treatment of systemic glucocorticoids plus short acting beta-2 agonist for treatment of acute wheezing provide additional…
- Trial name
- NCT01304901
- Testing
- montelukast 4 mg granule
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Kecioren Education and Training Hospital
Asthma
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an…
- Trial name
- REIMAGINE (NCT06041386)
- Testing
- Mepolizumab, Spirometry
- Where
- 65 sites in United States, Belgium and 7 more
- Volunteers
- 336 people
- Sponsor
- GlaxoSmithKline
Asthma in Children
Evaluation of Efficacy and Tolerance of JOE on 4 to 11 Years Old Asthmatic Patients of GINA 2,3,4 and 5 Grades
The main objective of this study is to evaluate efficacy and safety of patient's learning in self-taking of prescribed asthma maintenance treatments and provided by JOE (a new DTX), on the number of severe exacerbations in…
- Trial name
- JoeCare (NCT04942639)
- Testing
- JOE
- Where
- 13 sites in France
- Volunteers
- 213 people
- Sponsor
- Ludocare SAS
Asthma
Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics
Asthmatics who are significantly overweight tend to have more severe symptoms, more flare ups, and are more likely to have poorly-controlled asthma when compared to other asthmatics.
- Trial name
- GLITZ Asthma (NCT00634036)
- Testing
- pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Fernando Holguin
Asthma, Status Asthmaticus
Bilevel Positive Airway Pressure (BiPAP) for the Treatment of Moderate to Severe Acute Asthma Exacerbations
Bilevel Positive Airway Pressure (BiPAP) is increasingly being reported as an effective and safe method of respiratory support for children with severe asthma exacerbations unresponsive to standard therapies and with impending…
- Trial name
- NCT02347462
- Testing
- Bilevel Positive Airway Pressure (BiPAP) (Trilogy BiPAP, Philips Respironics), Standard care
- Where
- Canada
- Sponsor
- University of British Columbia
Asthma
Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma
The purpose of this study is to show whether mepolizumab given every 4 weeks intravenously (i.v.) can reduce the frequency of asthma exacerbations in subjects with severe asthma despite receiving high doses of standard asthma…
- Trial name
- DREAM (NCT01000506)
- Testing
- Mepolizumab 750, Mepolizumab 250, Mepolizumab 75
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 621 people
- Sponsor
- GlaxoSmithKline